VivoSeq
Oncology

Anaplastic Thyroid Cancer

3

Pipeline Programs↗

2

Active Trials↗

2

Companies Involved↗

Anaplastic Thyroid Cancer is an early-stage landscape with 3 programs across 2 companies. The most active players are Teva, Novartis.

Intelligence

Pipeline Metrics

Competitive Density

24/100

Pipeline Velocity

0/100

Mech. Concentration

33/100

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Teva logo

Teva

1 program

Phase 1Novartis logo

Novartis

2 programs

Phase 2

Pipeline

Programs by Phase

Preclinical
No programs
Phase 11

Paclitaxel

Teva

Phase 22

Dabrafenib

Novartis

Trametinib

Novartis

Phase 3
No programs
Approved
No programs

Analysis

Trial Status

2

clinical trials

Active, not recruiting2 · 100%

Clinical Trials

Trial Activity

A Pilot Study of Trametinib in Combination With Paclitaxel in the Treatment of Anaplastic Thyroid Cancer
Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT03085056·13 enrolled
A Pilot Study of the Addition of Cemiplimab, an Antibody to PD-1, to the Treatment of Subjects With BRAF-Mutant Anaplastic Thyroid Cancer Who Are No Longer Responding to Dabrafenib and Trametinib
Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT04238624·16 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)